Body Handbook Catalogue Profile Ranking
Gut BODY HANDBOOK
Gut ยท ยง87
SIBO (Bacterial Overgrowth)
SIBO is a real condition with a broken test. Bacteria that belong in the colon creep up into the small bowel, ferment your food before you absorb it, and leave you bloated and gassy. The catch: the breath test almost everyone gets catches barely half of true cases and flags plenty of healthy people Losurdo et al. 2020. So the crowd carrying a "SIBO diagnosis" is a muddle of people who have it, people who don't, and people wearing the label as an identity. The one thing that tells you which you are is whether you carry a risk factor that actually predicts overgrowth.
Condition Evidence Emerging Chapter Gut

The small intestine is meant to be nearly sterile. Stomach acid, a cleaning wave that sweeps the bowel between meals, and the valve guarding the colon all keep it that way. Break one and colon bacteria colonize upstream 1. Their hydrogen and methane are the bloat you feel.

Methane is its own beast. It comes from archaea, not bacteria, and it slows the bowel 2, so methane-positive overgrowth shows up as constipation and needs a different drug.

The test is the whole problem. You drink a sugar solution, the bacteria ferment it, you breathe out the gas. On paper it is clean. In practice the glucose version catches only about 55% of real cases and the lactulose version about 42% 3. When almost no one in the room truly has SIBO, most positive results are wrong. A positive means one thing coming from a GI doctor testing your scleroderma, and something else entirely coming from a wellness clinic testing your dinner bloat.

Who actually has it. The odds of true SIBO turn on whether you carry a predisposing condition. Without one, bloating and gas are "weakly predictive at best" 4 โ€” you may have something real, but probably not this.

If it does fit, treatment is short. First choice is rifaximin, a gut-targeted antibiotic โ€” 550 mg three times daily for 14 days, which clears the overgrowth in roughly six or seven of ten people 7. Methane-positive overgrowth needs neomycin added; the pair cleared it in 87% of patients versus about 30% for either alone 8. The best controlled evidence, from IBS-D, is honest about the size: about 41% improved versus 32% on placebo 9.

The clock is the tell. The whole workup โ€” test, two-week course, follow-up โ€” fits inside a month if it is going to work. Even after a clean result, about 44% of people test positive again within nine months 10, which is why fixing the cause and spacing your meals to let that cleaning wave finish matter more than the pill. A year into a "SIBO journey" with no durable relief is not a stubborn case. It is a wrong diagnosis.

No risk factor, still bloated? The strong evidence lives in IBS: a proper low-FODMAP trial, enteric-coated peppermint oil, gut-directed hypnotherapy, or a low-dose tricyclic at night. If any of these fixes it, whether you ever had SIBO stops mattering. Refractory elemental diet works too but is miserable 11.

The fine print โ€” when to skip it, and what people get wrong

What the wellness internet gets wrong. SIBO gets blamed for fatigue, brain fog, and rosacea; mainstream GI says the data don't support the leap 4. A positive breath test alone is not a diagnosis. Months-long "SIBO protocols" of herbals and biofilm disruptors aren't the treatment โ€” the real one is two weeks of antibiotic.

Where it goes off the rails. Treating a positive test in someone with no risk factor. Never deprescribing the PPI that caused it, so it returns each year. The DTC kit that sells you the test and a $400 herbal protocol from the same site.

References
  1. 1Pimentel et al. (2020). ACG Clinical Guideline: Small Intestinal Bacterial Overgrowth. American Journal of Gastroenterology. link
  2. 2Pimentel et al. (2006). Methane, a gas produced by enteric bacteria, slows intestinal transit and augments small intestinal contractile activity. American Journal of Physiology - Gastrointestinal and Liver Physiology. link
  3. 3Losurdo et al. (2020). Breath Tests for the Non-invasive Diagnosis of Small Intestinal Bacterial Overgrowth: A Systematic Review With Meta-analysis. Journal of Neurogastroenterology and Motility. link
  4. 4Quigley et al. (2020). AGA Clinical Practice Update on Small Intestinal Bacterial Overgrowth: Expert Review. Gastroenterology. link
  5. 5Marie et al. (2009). Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology. link
  6. 6Lo WK, Chan WW (2013). Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clinical Gastroenterology and Hepatology. link
  7. 7Gatta L, Scarpignato C (2017). Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Alimentary Pharmacology and Therapeutics. link
  8. 8Low et al. (2010). A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. Journal of Clinical Gastroenterology. link
  9. 9Pimentel et al. (2011). Rifaximin therapy for patients with irritable bowel syndrome without constipation. New England Journal of Medicine. link
  10. 10Lauritano et al. (2008). Small intestinal bacterial overgrowth recurrence after antibiotic therapy. American Journal of Gastroenterology. link
  11. 11Pimentel et al. (2004). A 14-day elemental diet is highly effective in normalizing the lactulose breath test. Digestive Diseases and Sciences. link
ยท
87